Identification | More | [Name]
Dilthiazem hydrochloride | [CAS]
33286-22-5 | [Synonyms]
(2S,3S)-(+)-CIS-3-(ACETOXY)-5-(2-DIMETHYLAMINOETHYL)-2,3-DIHYDRO-2-(4-METHOXYPHENYL)-1,5-BENZOTHIAZEPIN-4(5H)-ONE HYDROCHLORIDE (2S,3S)-(+)-CIS-3-(ACETOXY)-5-(2-DIMETHYLAMINOETHYL)-2,3-DIHYDRO-2-(4-METHOXYPHENYL)-1,5-BENZOTHIAZEPIN-4(5H)-ONE, HCL (2S-CIS)-3-(ACETYLOXY)-5-[2-(DIMETHYLAMINO)ETHYL]-2,3-DIHYDRO-2-(4-METHOXYPHENYL)-1,5-BENZOTHIAZEPIN-4(5H)-ONE HYDROCHLORIDE CIS-(+)-3-(ACETYLOXY)-5-[2-(DIMETHYLAMINO)ETHYL]-2,3-DIHYDRO-2-(4-METHOXY-PHENYL)-1,5-BENZOTHIAZEPIN-4(5H)-ONE HYDROCHLORIDE CRD-401 DILTHIAZEM HYDROCHLORIDE DILTIAZEM-D3 HCL DILTIAZEM HCL DILTIAZEM HYDROCHLORIDE L-CIS-DILTIAZEM HCL 1,5-benzothiazepin-4(5h)-one,2,3-dihydro-3-(acetyloxy)-5-(2-(dimethylamino)eth 2,3-dihydro-3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-5-benzothiazepin-4(5h)-one altiazem anginyl angizem britiazim bruzem calcicard cardizem dilpral | [EINECS(EC#)]
251-443-3 | [Molecular Formula]
C22H27ClN2O4S | [MDL Number]
MFCD00069252 | [Molecular Weight]
450.98 | [MOL File]
33286-22-5.mol |
Chemical Properties | Back Directory | [Appearance]
Fine Needles | [Melting point ]
212-214 °C
| [alpha ]
D24 +98.3 ± 1.4° (c = 1.002 in methanol) | [density ]
1.30 g/cm3 | [refractive index ]
118 ° (C=1, H2O) | [Fp ]
2℃ | [storage temp. ]
2-8°C
| [solubility ]
Freely soluble in water, in methanol and in methylene chloride, slightly soluble in anhydrous ethanol. | [form ]
Powder | [color ]
White to off-white | [PH]
pH (10g/l, 25℃) : 4.3~5.3 | [Water Solubility ]
soluble | [Usage]
An antianginal, antihypertensive. Regulates Calcium release from intracellular stores in neutrophils | [Merck ]
13,3226 | [BRN ]
4228706 | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months. | [CAS DataBase Reference]
33286-22-5(CAS DataBase Reference) | [EPA Substance Registry System]
1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, hydrochloride (1:1), (2S,3S)- (33286-22-5) |
Safety Data | Back Directory | [Hazard Codes ]
Xn,Xi | [Risk Statements ]
R22:Harmful if swallowed. R40:Limited evidence of a carcinogenic effect. R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S36:Wear suitable protective clothing . S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) . S36/37:Wear suitable protective clothing and gloves . S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . | [RIDADR ]
3249 | [WGK Germany ]
3
| [RTECS ]
DL0310000
| [F ]
8-10 | [HazardClass ]
6.1(b) | [PackingGroup ]
III | [HS Code ]
29349990 | [Toxicity]
LD50 in male, female mice, male, female rats (mg/kg): 61, 58, 38, 39 i.v.; 260, 280, 520, 550 s.c.; 740, 640, 560, 610 orally (Nagao, 1972) |
Hazard Information | Back Directory | [Description]
Diltiazem HCl (33286-22-5) is a?non-dihydropyridine-type blocker of L-type Ca2+ channels.1,2 Reduces Ca2+ oscillations in subcellular compartments in vascular smooth muscle cells.3?Also blocks P-type Ca2+ channels in freshly dissociated rat cerebellar Purkinje neurons.4 Clinically useful antihypertensive agent.5?Cell permeable. | [Chemical Properties]
Fine Needles | [Originator]
Herbesser,TANABE SEIYAKU,Japan,1974 | [Uses]
An antianginal, antihypertensive. Regulates Calcium release from intracellular stores in neutrophils | [Uses]
antihypertensive, sedative, antibacterial | [Uses]
Diltiazem Hydrochloride is a calcium channel blocker with vasodilating activity. Anti-anginal; anti-hypertensive; anti-arrhythmic (class IV). | [Uses]
Peripheral Vasodilator | [Definition]
ChEBI: A hydrochloride salt resulting from the reaction of equimolar amounts of diltiazem and hydrogen chloride. A calcium-channel blocker and vasodilator, it is used in the management of angina pectoris and hypertension. | [Manufacturing Process]
β-Diethylaminoethyl chloride is condensed with 2-(4-methoxyphenyl)-3-
hydroxy-2,3-dihydro-1,5-benzothiazepin-4(5H)-one in a first step. Then a
mixture of 1.5 grams of 2-(4-methoxyphenyl)-3-hydroxy-5-(βdimethylaminoethyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one and 20 ml of
acetic anhydride was heated on a water bath for 5 hours. The reaction
mixture was evaporated under reduced pressure to remove acetic anhydride
and the concentrated product was poured into ice water. The resulting mixture
was made alkaline with sodium bicarbonate and extracted with chloroform.
The chloroform layer was dried and evaporated to remove the solvent. The
residue was dissolved in acetone, and an ethanol solution containing hydrogen
chloride was added thereto producing 1.53 grams of 2-(4-methoxyphenyl)3-
acetoxy-5-(β-dimethylaminoethyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one
hydrochloride having a melting point from 187° to 188°C. The starting material is made by reacting 4-methoxybenzaldehyde with ethyl
chloroacetate; that product with sodium ethoxide; and that product with 2-
aminothiophenol. | [Brand name]
Cardizem (Biovail); Cartia (Andrx); Dilacor (Watson); Diltzac (Apotex); Taztia (Andrx); Tiazac (Biovail). | [Therapeutic Function]
Coronary vasodilator | [General Description]
Diltiazem hydrochloride,(+)-cis-3-(acetoxy)-5-[2(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)1,5-benzothiazepin-4(5H)one hydrochloride(Cardizem), was developed and introduced inJapan as a cardiovascular agent to treat angina pectoris. Itwas observed to dilate peripheral arteries and arterioles. Thedrug increases myocardial oxygen supply by relieving coronaryartery spasm and reduces myocardial oxygen demandby decreasing heart rate and reducing overload. Diltiazemhydrochloride is used in patients with variant angina. Thedrug has electrophysiological properties similar to those ofverapamil and is used in clinically similar treatment conditionsas an antiarrhythmic agent, but it is less potent. The drug is absorbed rapidly and almost completely fromthe digestive tract. It reaches peak plasma levels within 1hour after administration in gelatin capsules. Oral formulationson the market are sustained-release preparations providingpeak plasma levels 3 to 4 hours after administration. | [Biological Activity]
Antihypertensive and cardioprotective agent; an inhibitor of L-type Ca 2+ channels. | [Biochem/physiol Actions]
Product does not compete with ATP. | [Clinical Use]
Calcium-channel blocker: Prophylaxis and treatment of angina Hypertension | [Metabolism]
Diltiazem is almost completely absorbed from the
gastrointestinal tract after oral doses, but undergoes
extensive first-pass hepatic metabolism resulting in a
bioavailability of about 40%. It is extensively metabolised
in the liver, mainly by the cytochrome P450 isoenzyme
CYP3A4; one of the metabolites, desacetyldiltiazem,
has been reported to have 25-50% of the activity of the
parent compound About 2-4% of a dose is excreted in urine as unchanged
diltiazem with the remainder excreted as metabolites in
bile and urine. | [storage]
Store at RT | [Mode of action]
Diltiazem Hydrochloride is a benzothiazepine calcium channel blocking agent. Diltiazem hydrochloride inhibits the transmembrane influx of extracellular calcium ions into select myocardial and vascular smooth muscle cells, causing dilatation of coronary and systemic arteries and decreasing myocardial contractility. Because of its vasodilatory activity, this agent has been shown to improve the microcirculation in some tumors, thereby potentially improving the delivery of antineoplastic agents to tumor cells. | [References]
1) Kraus?et al.?(1998),?Molecular mechanism of diltiazem interaction with L-type Ca2+ channels; J. Biol. Chem.,?273?27205
2) Godfraind?et al. (1986),?Calcium antagonism and calcium entry blockade; Pharmacol. Rev.,?38?321
3) Fedoryak?et al.?(2004),?Spontaneous Ca2+ oscillations in subcellular compartments of vascular smooth muscle cells rely on different Ca2+ pools; Cell Res.,?14?379
4) Ishibashi?et al. (1995),?Block of P-type Ca2+ channels in freshly dissociated rat cerebellar Purkinje neurons by diltiazem and verapamil; Brain Res.,?695?88
5) Chaffman and Bogden (1985),?Diltiazem. A review of its pharmacological properties and therapeutic efficacy; Drugs,?29?387 |
|
|